1. IgA nephropathy is a glomerular disease with variable course
Charité’s dedicated IgA nephropathy clinic describes IgA nephropathy as a common form of glomerulonephritis that can present with visible or microscopic blood in the urine, proteinuria, high blood pressure and declining kidney function. The course varies substantially between patients.
2. Kidney biopsy can be central to diagnosis and risk assessment
Charité notes that a kidney tissue sample is often needed to confirm IgA nephropathy, assess prognosis and inform treatment options. For an international second opinion, the original pathology report and—where feasible through the receiving center’s secure process—slides or digital pathology may be important.
3. Treatment should separate supportive care from immune-directed therapy
The Charité clinic distinguishes supportive treatment focused on factors such as blood pressure and proteinuria from selected immune-modifying treatment. A second opinion should explain why a medicine is being considered, what disease activity or risk it is intended to address and how treatment response and adverse effects will be monitored.
4. Glomerular disease can overlap with systemic disease
Proteinuria, hematuria and reduced kidney function can occur with vasculitis, lupus and other systemic or complement-mediated disorders. Charité’s rare-kidney-disease center lists a broad spectrum of glomerular, vascular, hereditary and immune-mediated conditions, illustrating why the precise diagnosis matters.
5. Records to prepare
Prepare a timeline rather than a large unsorted archive.
- Kidney biopsy pathology report and date
- Creatinine/eGFR trend
- Urine protein or albumin trend
- Blood-pressure values
- Relevant immune/serologic tests
- Current and previous immunosuppressive or kidney-protective therapy
Official and primary sources
Sources last checked 2026-09-21.